In January 2025, the Trump administration implemented a temporary freeze on federal financial assistance programs, including grants and loans, to review their alignment with the administration’s priorities. This action, though temporarily halted by a federal judge, has significant implications for clinical trials that rely heavily on federal funding.
Clinical trials are essential for advancing medical science and developing new treatments. Many of these trials depend on
federal funding from agencies such as the National Institutes of Health (NIH). The funding freeze has led to delayed research, which means ongoing studies face interruptions due to halted disbursements, potentially delaying critical medical advancements. It has also led to enrollment holds, new patient enrollments in clinical trials have been paused, affecting participants seeking experimental treatments. Additionally, there are new operational challenges, as research institutions are grappling with budget uncertainties, leading to potential furloughs of research staff and suspension of projects.
Given the evolving nature of federal policies, organizations involved in clinical trials should take proactive steps to mitigate risks posed to human subjects. It is important to engage with attorneys who specialize in healthcare and federal regulations to understand the implications of funding changes and to navigate compliance issues effectively. Additionally, it is important to assess existing contracts with federal agencies to identify clauses related to funding interruptions and develop contingency plans.
A key part of preparation for disruptions is the development of strategies to manage financial and operational challenges that may arise when funding is uncertain, including by diversifying funding sources and prioritizing critical research activities. One often overlooked but critical “best practice” is to ensure that the informed consent form (ICF) for clinical trial participants anticipates potential disruptions to trials, whether caused by a funding shortfall or FDA-mandated halt. ICFs should clearly outline what will happen in the event of an abrupt trial suspension, including in provisions for continued patient care and access to treatment, and, where applicable, in guidance for tapering off investigational drugs safely. This is particularly crucial for studies involving medications that require gradual dose reductions to prevent withdrawal symptoms or other adverse health effects.
By taking these measures, clinical trial stakeholders can minimize the impact of funding freezes on both research progress and patient safety, ensuring that ethical and legal responsibilities are upheld even in times of uncertainty.